CDMRP Neurofibromatosis New Investigator Award
ID: 355152Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355152
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis New Investigator Award, aimed at supporting innovative research addressing neurofibromatosis (NF). This grant is designed to assist both early-stage and established investigators transitioning into NF research, with a focus on advancing understanding, diagnosis, and treatment of NF types 1, 2, and schwannomatosis, while encouraging diverse research approaches that enhance clinical outcomes. The total funding available for this program is $2.88 million, with an anticipated direct cost limit of $450,000 per project, and applications are due by October 3, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524NFRPNIA_GG.pdf
    The Department of Defense (DOD) has announced the FY24 Neurofibromatosis New Investigator Award under the Defense Health Program, aimed at supporting innovative research that addresses neurofibromatosis (NF). The program provides an opportunity for new and established investigators to pursue research with potentially high impacts relevant to military members and the general public. The total funding available for FY24 is $25 million, with an anticipated direct cost limit of $450,000 for each project. Eligible applicants include researchers affiliated with both extramural and intramural organizations, focusing on advancing understanding, diagnosis, and treatment of NF types 1, 2, and schwannomatosis. The award encourages diverse research approaches, especially those enhancing clinical outcomes, and prohibits clinical trial proposals. The submission process involves a two-step application procedure: submission of a pre-application followed by a full application. Applications will be evaluated based on personnel qualifications, research feasibility, innovation, and potential impact. The peer review process will lead to final funding recommendations, emphasizing the alignment of proposals with the program's strategic goals and areas of emphasis. This program represents significant federal support for ongoing NF research and aims to elevate the quality of care for those affected by the condition while engaging a wide range of research endeavors.
    Similar Opportunities
    DOD Glioblastoma, Transformative Consortium Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Glioblastoma Transformative Consortium Award, aimed at advancing research to improve outcomes for glioblastoma patients. This grant seeks proposals for innovative, multidisciplinary projects that collectively address a central hypothesis, requiring collaboration among at least four distinct projects and the inclusion of a consumer advocate. With an estimated total program funding of $9 million, the application process includes a pre-application deadline of December 23, 2024, and a full application deadline of January 13, 2025. Interested applicants can reach the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity for clinical trials aimed at addressing unmet needs in rare neurodegenerative diseases through the Notice of Funding Opportunity (NOFO) RFA-FD-25-001. This initiative, mandated by the ACT for ALS Act, seeks to support trials that evaluate the efficacy and safety of products for new indications or changes in labeling, with the goal of increasing the number of approved treatments for these conditions affecting fewer than 200,000 individuals in the U.S. Eligible applicants include various organizations such as higher education institutions and non-profits, with funding amounts capped at $650,000 for standard applications and up to $900,000 for innovative approaches. Interested parties should note that applications will be accepted starting August 23, 2024, with letters of intent and full applications due by October 22, 2024. For further inquiries, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at enhancing the understanding of the neurological effects associated with infection-related chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This initiative encourages research projects that explore the neurological and psychiatric manifestations of these illnesses, with a particular interest in studies that may identify common neuropsychiatric mechanisms across multiple conditions, although applications focusing on individual illnesses are also welcome. The NOFO is anticipated to be released in Fall 2024, with applications due in Winter 2025, and will utilize the R21 grant mechanism. Interested applicants should prepare for a project start date expected in December 2025, with further details to be outlined in the forthcoming announcement.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Active
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.